您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Ulipristal Acetate-d6
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ulipristal Acetate-d6
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ulipristal Acetate-d6图片
CAS NO:1621894-64-1
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
An internal standard for the quantification of ulipristal acetate
Cas No.1621894-64-1
别名CDB-2914-d6
Canonical SMILESO=C1CCC2=C3[C@@]([C@@](CC[C@]4(OC(C)=O)C(C)=O)([H])[C@]4(C)C[C@@H]3C5=CC=C(N(C([2H])([2H])[2H])C([2H])([2H])[2H])C=C5)([H])CCC2=C1
分子式C30H31D6NO4
分子量481.7
溶解度Methanol: soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Ulipristal acetate-d6is intended for use as an internal standard for the quantification of ulipristal acetate by GC- or LC-MS. Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to the human progesterone receptors PR-A and PR-B (EC50s = 8.5 and 7.7 nM, respectively), rabbit uterine PR (EC50= 13.6 nM), and rabbit thymic glucocorticoid receptor (GR; EC50= 15.4 nM).1It is selective for human progesterone receptors over the human estrogen receptor (ER; EC50= >10,000 nM). It inhibits growth of IGROV-1 and SK-OV-3 human ovarian cancer cells (IC50s = 15.5 and 31.5 μM, respectively) even after resistance to combined cisplatin and paclitaxel treatment has developed.2Ulipristal acetate reverses the proliferative effect of progesterone on patient-derived germline mutantBRCA1breast tissue xenografts in ovariectomized athymic mice.3Ulipristal acetate (40 mg/kg, i.p.) administered to female mice within 6 hours of human chorionic gonadotropin (hCG) treatment inhibits ovulation.4Formulations containing ulipristal acetate have been used as emergency contraceptives and to treat uterine fibroids.

1.Attardi, B.J., Burgenson, J., Hild, S.A., et al.In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristoneJ. Steroid Biochem. Mol. Biol.88(3)277-288(2004) 2.Gamarra-Luques, C.D., Hapon, M.B., Goyeneche, A., et al.Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicityJ. Ovarian Res.7:45(2014) 3.Communcal, L., Vilasco, M., Hugon-Rodin, J., et al.Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: Benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutationsOncotarget7(29)45317-45330(2016) 4.Nallasamy, S., Kim, J., Sitruk-Ware, R., et al.Ulipristal blocks ovulation by inhibiting progesterone receptor-dependent pathways intrinsic to the ovaryReprod. Sci.20(4)371-381(2013)